Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VG081821AC monotherapy vs placebo in early-to-moderate Parkinson’s disease (Phase IIb, China)
ChiCTR2600127436Phase 2Not yet recruiting
- Sponsor
- Xuanwu Hospital
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of VG081821AC in Parkinson's disease (PD) (4 arms), sponsored by Xuanwu Hospital. Primary endpoint: Change from baseline in MDS-UPDRS Part III (Motor Examination) scores at Week 12 between treatment and placebo groups. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
VG081821AC
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on ChiCTR2600127436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127436.